Data / Drug companies / Method Pharmaceuticals, LLC
Method Pharmaceuticals, LLC: 110 products in the FDA NDC directory, labeler code 58657
Method Pharmaceuticals, LLC (labeler code 58657) lists 110 products in the FDA National Drug Code Directory, covering 34 finished drugs by generic name. By type: 97 prescription drugs, 12 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 15, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 58657
- Products in commercial distribution
- 110
- Packages
- 173
- Finished drugs by generic name
- 34
- Prescription products
- 97
- Over the counter products
- 12
- Controlled substance products
- Schedule III 8, Schedule V 1
- Flagged as original packager
- 108 of 108 products that carry the flag
- Started marketing in the last 12 months
- 19
- Earliest marketing start
- April 1, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 65 | 59.1% |
| Other unapproved drugs | 32 | 29.1% |
| Over the counter monograph drugs | 12 | 10.9% |
| Drugs for further processing | 1 | 0.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 97 | 88.2% |
| Over the counter drugs | 12 | 10.9% |
| Drugs for further processing | 1 | 0.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 61 | 55.5% |
| Liquid | 15 | 13.6% |
| Tablet, film coated | 10 | 9.1% |
| Solution | 4 | 3.6% |
| Injection | 4 | 3.6% |
| Capsule | 4 | 3.6% |
| Tablet, chewable | 3 | 2.7% |
| Cream | 3 | 2.7% |
| Tablet, coated | 2 | 1.8% |
| Syrup | 2 | 1.8% |
| Granule | 1 | 0.9% |
| Solution/ drops | 1 | 0.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Finjozy | 58657-275 | Tablet | Generic drugs (ANDA) | October 15, 2026 |
| Pyridostigmine bromide | 58657-809 | Granule | Drugs for further processing | August 20, 2026 |
| Relgaabi | 58657-234 | Capsule | Generic drugs (ANDA) | April 15, 2026 |
| Relgaabi | 58657-233 | Capsule | Generic drugs (ANDA) | April 15, 2026 |
| Relgaabi | 58657-231 | Capsule | Generic drugs (ANDA) | March 9, 2026 |
| Sodium Chloride | 58657-119 | Tablet | Over the counter monograph drugs | February 13, 2026 |
| Metformin Hydrochloride | 58657-727 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Metformin Hydrochloride | 58657-726 | Tablet | Generic drugs (ANDA) | February 9, 2026 |
| Phenylephrine Hydrochloride | 58657-853 | Injection | Generic drugs (ANDA) | February 1, 2026 |
| Phenylephrine Hydrochloride | 58657-852 | Injection | Generic drugs (ANDA) | February 1, 2026 |
| Phenylephrine Hydrochloride | 58657-851 | Injection | Generic drugs (ANDA) | February 1, 2026 |
| Metolazone | 58657-942 | Tablet | Generic drugs (ANDA) | January 28, 2026 |
| Metolazone | 58657-941 | Tablet | Generic drugs (ANDA) | January 28, 2026 |
| Metolazone | 58657-940 | Tablet | Generic drugs (ANDA) | January 28, 2026 |
| Levetiracetam | 58657-860 | Injection | Generic drugs (ANDA) | December 15, 2025 |
| Captopril | 58657-938 | Tablet | Generic drugs (ANDA) | December 1, 2025 |
| Captopril | 58657-937 | Tablet | Generic drugs (ANDA) | December 1, 2025 |
| Captopril | 58657-936 | Tablet | Generic drugs (ANDA) | December 1, 2025 |
| Captopril | 58657-935 | Tablet | Generic drugs (ANDA) | December 1, 2025 |
| Metronidazole | 58657-939 | Tablet | Generic drugs (ANDA) | July 1, 2025 |
| Metronidazole | 58657-934 | Tablet | Generic drugs (ANDA) | July 1, 2025 |
| Metronidazole | 58657-933 | Tablet | Generic drugs (ANDA) | July 1, 2025 |
| Labetalol Hydrochloride | 58657-908 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Labetalol Hydrochloride | 58657-907 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
| Labetalol Hydrochloride | 58657-906 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.